BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...of infectious diseases including COVID-19. BC Staff Acutus Medical Inc. Quest PharmaTech Inc. Foghorn...
BioCentury | Dec 8, 2017
Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

...In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct...
...were not disclosed. Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Elizabeth S. Eaton oregovomab Zejula Quest PharmaTech Inc. Tesaro...
BioCentury | Sep 14, 2017
Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

...The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab...
...is expected to enroll about 10 patients. Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...Safety; cellular immune response and overall survival (OS) Status: Phase I/II started Milestone: NA Alicia Parker oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
BioCentury | Jul 5, 2017
Company News

Management tracks

...which Bio-Rad Laboratories Inc. (NYSE:BIO) acquired in February. The OncoQuest Inc. immuno-oncology subsidiary of Quest PharmaTech Inc....
BioCentury | May 17, 2017
Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

...control rate (DCR) and overall survival (OS). Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...disease control rate (DCR) and overall survival (OS) Status: Phase Ib/IIa started Milestone: NA Julian Zhu oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
BioCentury | Feb 10, 2017
Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

...alone. There was no significant difference in the incidence of adverse events between treatment groups. Quest PharmaTech Inc....
...immunogenicity, clinical response, overall survival (OS) and safety Status: Interim Phase IIb data Milestone: NA Chris Lieu oregovomab Quest PharmaTech Inc. CA...
BioCentury | Apr 4, 2016
Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

...monoclonal immunoglobulins. OncoVent will initially focus on pancreatic cancer. Hepalink did not respond to inquiries. Quest PharmaTech Inc....
BioCentury | Dec 7, 2015
Financial News

Quest Pharma completes private placement of convertible preferred stock

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-11-18 Type: Private placement of convertible preferred stock Raised: $13 million Shares: 3.5 million Price: $3.74 Investor: Shenzhen Hepalink Pharmaceutical Co. Ltd. Note:...
BioCentury | Oct 19, 2015
Financial News

Quest Pharma completes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-10-13 Type: Private placement Raised: C$2 million ($1.5 million) Shares: 25 million Price: C$0.08 Shares after offering: 150.4 million Investor: Shenzhen Hepalink Pharmaceutical...
BioCentury | Aug 3, 2015
Financial News

Quest Pharma completes private placement of units

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-07-27 Type: Private placement of units Raised: C$1 million ($769,600) Units: 16.7 million Price: C$0.06 (unit) Shares after offering: 125.4 million Investors: Institutional...
Items per page:
1 - 10 of 42
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...of infectious diseases including COVID-19. BC Staff Acutus Medical Inc. Quest PharmaTech Inc. Foghorn...
BioCentury | Dec 8, 2017
Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

...In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct...
...were not disclosed. Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Elizabeth S. Eaton oregovomab Zejula Quest PharmaTech Inc. Tesaro...
BioCentury | Sep 14, 2017
Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

...The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab...
...is expected to enroll about 10 patients. Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...Safety; cellular immune response and overall survival (OS) Status: Phase I/II started Milestone: NA Alicia Parker oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
BioCentury | Jul 5, 2017
Company News

Management tracks

...which Bio-Rad Laboratories Inc. (NYSE:BIO) acquired in February. The OncoQuest Inc. immuno-oncology subsidiary of Quest PharmaTech Inc....
BioCentury | May 17, 2017
Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

...control rate (DCR) and overall survival (OS). Oregovomab is a high-affinity mAb targeting CA 125. Quest PharmaTech Inc....
...disease control rate (DCR) and overall survival (OS) Status: Phase Ib/IIa started Milestone: NA Julian Zhu oregovomab OvaRex OvaRex Mab Quest PharmaTech Inc. CA...
BioCentury | Feb 10, 2017
Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

...alone. There was no significant difference in the incidence of adverse events between treatment groups. Quest PharmaTech Inc....
...immunogenicity, clinical response, overall survival (OS) and safety Status: Interim Phase IIb data Milestone: NA Chris Lieu oregovomab Quest PharmaTech Inc. CA...
BioCentury | Apr 4, 2016
Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

...monoclonal immunoglobulins. OncoVent will initially focus on pancreatic cancer. Hepalink did not respond to inquiries. Quest PharmaTech Inc....
BioCentury | Dec 7, 2015
Financial News

Quest Pharma completes private placement of convertible preferred stock

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-11-18 Type: Private placement of convertible preferred stock Raised: $13 million Shares: 3.5 million Price: $3.74 Investor: Shenzhen Hepalink Pharmaceutical Co. Ltd. Note:...
BioCentury | Oct 19, 2015
Financial News

Quest Pharma completes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-10-13 Type: Private placement Raised: C$2 million ($1.5 million) Shares: 25 million Price: C$0.08 Shares after offering: 150.4 million Investor: Shenzhen Hepalink Pharmaceutical...
BioCentury | Aug 3, 2015
Financial News

Quest Pharma completes private placement of units

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta Business: Dermatology, Cancer, Diagnostic Date completed: 2015-07-27 Type: Private placement of units Raised: C$1 million ($769,600) Units: 16.7 million Price: C$0.06 (unit) Shares after offering: 125.4 million Investors: Institutional...
Items per page:
1 - 10 of 42